TASK: CLINICAL CLASSIFICATION OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (ADRD)

OBJECTIVE:
You are an expert geriatric neurologist and neuropsychologist performing a comprehensive clinical assessment to classify whether a patient has Alzheimer's Disease and Related Dementias (ADRD) versus Non-ADRD conditions.

This is a BINARY CLASSIFICATION task:
- **ADRD**: Alzheimer's Disease, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia, Mixed Dementia, or other neurodegenerative dementias
- **Non-ADRD**: Cognitive impairment from other causes OR no dementia

PATIENT CONTEXT:
- Age: {age}
- Gender: {gender}
- Race/Ethnicity: {race}
- Education Level: {education_years} years

CLINICAL RECORD:
{clinical_text}

{rag_outputs}

{function_outputs}

{extras_outputs}

═══════════════════════════════════════════════════════════════════════════
CLASSIFICATION FRAMEWORK
═══════════════════════════════════════════════════════════════════════════

PHASE 1: SYSTEMATIC CLINICAL DATA EXTRACTION

Extract ALL relevant information for ADRD assessment:

A. COGNITIVE ASSESSMENT FINDINGS
   - **Formal Testing Scores**:
     * MMSE (Mini-Mental State Examination): Score /30
     * MoCA (Montreal Cognitive Assessment): Score /30
     * CDR (Clinical Dementia Rating): Global score and domain scores
     * Clock Drawing Test results
     * Other neuropsychological testing (memory, language, executive function, visuospatial)

   - **Cognitive Domains Affected**:
     * Memory: Short-term, long-term, episodic, semantic
     * Language: Naming, fluency, comprehension
     * Executive Function: Planning, organization, abstract thinking
     * Visuospatial: Spatial awareness, visual processing
     * Attention/Concentration
     * Processing Speed

   - **Onset and Progression**:
     * Timeline: When did symptoms start? (months/years ago)
     * Progression: Gradual vs stepwise vs rapid
     * Rate: Slowly progressive, stable, fluctuating

B. FUNCTIONAL ASSESSMENT
   - **Activities of Daily Living (ADL)**:
     * Basic ADLs: Bathing, dressing, toileting, feeding, transferring
     * Independent vs requires assistance vs dependent

   - **Instrumental ADLs (IADL)**:
     * Managing finances, medications, shopping, cooking, driving
     * Phone use, housework, transportation

   - **Functional Decline Pattern**:
     * Early loss of IADLs suggests dementia
     * Preserved basic ADLs in early stages
     * Progressive decline over time

C. BEHAVIORAL AND PSYCHIATRIC SYMPTOMS (BPSD)
   - Apathy, depression, anxiety
   - Agitation, aggression, irritability
   - Hallucinations (visual in LBD, less common in AD)
   - Delusions, paranoia
   - Sleep disturbances, sundowning
   - Wandering, disinhibition

D. NEUROLOGICAL EXAMINATION
   - **Motor Findings**:
     * Parkinsonism (rigidity, bradykinesia, tremor) → suggests LBD or vascular
     * Gait abnormalities, falls
     * Primitive reflexes (grasp, snout, palmomental)

   - **Focal Neurological Deficits**:
     * Weakness, sensory loss → suggests stroke/vascular
     * Asymmetric findings → vascular dementia

   - **Extrapyramidal Signs**:
     * Present early in LBD, late in AD

E. NEUROIMAGING FINDINGS
   - **CT/MRI Brain**:
     * Atrophy pattern: Medial temporal (hippocampus) → AD
     * Cortical vs subcortical atrophy
     * White matter hyperintensities → vascular
     * Lacunar infarcts, territorial infarcts → vascular dementia
     * Frontal/temporal atrophy → FTD

   - **PET Scan** (if available):
     * FDG-PET: Hypometabolism in temporo-parietal regions → AD
     * Amyloid PET: Positive → AD pathology
     * Tau PET: Tau deposition pattern

   - **SPECT**: Perfusion patterns

F. BIOMARKERS (if available)
   - **CSF Analysis**:
     * Low Aβ42 (amyloid-beta) → AD
     * High total tau and phospho-tau → AD
     * Aβ42/Aβ40 ratio

   - **Blood Biomarkers**:
     * Plasma p-tau, Aβ levels (emerging)

G. LABORATORY WORKUP
   - **Rule Out Reversible Causes**:
     * Vitamin B12 deficiency
     * Thyroid dysfunction (TSH, free T4)
     * Metabolic: Sodium, calcium, glucose
     * Renal/hepatic function
     * Syphilis (RPR/VDRL), HIV (if risk factors)

   - **Supporting Labs**:
     * CBC: Anemia
     * Inflammatory markers: ESR, CRP

H. MEDICAL HISTORY
   - **Vascular Risk Factors**:
     * Hypertension, diabetes, hyperlipidemia
     * Stroke/TIA history
     * Atrial fibrillation, coronary artery disease
     * Smoking history

   - **Family History**:
     * First-degree relatives with dementia
     * Early-onset dementia (<65 years) → genetic factors
     * Specific patterns (AD, FTD)

   - **Other Relevant History**:
     * Head trauma, chronic alcohol use
     * Depression history (can mimic dementia)
     * Medications causing cognitive impairment

I. CLINICAL PRESENTATION PATTERNS
   - **Alzheimer's Disease**:
     * Insidious onset, gradual progression
     * Memory loss predominant (episodic memory first)
     * Language, visuospatial problems later
     * Preserved motor function until late

   - **Vascular Dementia**:
     * Stepwise decline, plateaus
     * Associated with strokes/TIAs
     * Executive dysfunction prominent
     * Focal neurological signs

   - **Lewy Body Dementia**:
     * Fluctuating cognition
     * Visual hallucinations (early, detailed)
     * Parkinsonism (often concurrent)
     * REM sleep behavior disorder
     * Autonomic dysfunction

   - **Frontotemporal Dementia**:
     * Early behavioral changes (disinhibition, apathy)
     * Language variant: Progressive non-fluent aphasia, semantic dementia
     * Relatively preserved memory initially
     * Young onset (<65 common)

═══════════════════════════════════════════════════════════════════════════
PHASE 2: DIAGNOSTIC CRITERIA APPLICATION
═══════════════════════════════════════════════════════════════════════════

Apply established diagnostic criteria:

A. NIA-AA CRITERIA (2011/2018)
   - Dementia: Cognitive/behavioral symptoms that:
     1. Interfere with work or usual activities
     2. Decline from previous levels
     3. Not explained by delirium or major psychiatric disorder

   - Probable AD Dementia:
     * Meets dementia criteria
     * Insidious onset (months to years)
     * Clear-cut history of worsening cognition
     * Initial and prominent cognitive deficits in:
       - Amnestic presentation (most common): Memory + ≥1 other domain
       - Non-amnestic: Language, visuospatial, or executive dysfunction

B. DSM-5 CRITERIA
   - Major Neurocognitive Disorder:
     * Significant cognitive decline from previous level
     * Interferes with independence in everyday activities
     * Not occurring exclusively during delirium
     * Not better explained by other mental disorder

   - Mild Neurocognitive Disorder:
     * Modest cognitive decline
     * Does NOT interfere with independence
     * Patient or informant concern + objective evidence

C. VASCULAR DEMENTIA CRITERIA
   - Temporal relationship between stroke and cognitive decline
   - Imaging evidence of cerebrovascular disease
   - Exclude other causes

D. LEWY BODY DEMENTIA CRITERIA (2017 Consensus)
   - Progressive cognitive decline interfering with function
   - Core features (≥2 for probable):
     * Fluctuating cognition
     * Visual hallucinations
     * REM sleep behavior disorder
     * Parkinsonism
   - Supportive features: Neuroleptic sensitivity, falls, syncope

═══════════════════════════════════════════════════════════════════════════
PHASE 3: DIFFERENTIAL DIAGNOSIS
═══════════════════════════════════════════════════════════════════════════

Consider and rule out Non-ADRD causes:

A. DELIRIUM
   - Acute onset, fluctuating course
   - Inattention prominent
   - Altered level of consciousness
   - Reversible with treatment of underlying cause

B. DEPRESSION ("PSEUDODEMENTIA")
   - Depressive symptoms prominent
   - "Don't know" answers (vs confabulation in dementia)
   - Subjective cognitive complaints > objective findings
   - May improve with antidepressant treatment

C. MILD COGNITIVE IMPAIRMENT (MCI)
   - Cognitive decline but preserves independence
   - Normal ADLs
   - May progress to dementia or remain stable

D. NORMAL AGING
   - Mild forgetfulness, slower processing
   - Does NOT interfere with function
   - No progressive decline

E. MEDICATION-INDUCED COGNITIVE IMPAIRMENT
   - Anticholinergics, benzodiazepines, opioids
   - Temporal relationship with medication start
   - Improves with discontinuation

F. METABOLIC/TOXIC CAUSES
   - B12 deficiency, hypothyroidism
   - Hepatic/renal encephalopathy
   - Alcohol-related dementia

G. STRUCTURAL LESIONS
   - Normal pressure hydrocephalus (triad: gait, incontinence, dementia)
   - Brain tumor, subdural hematoma

H. INFECTIOUS/INFLAMMATORY
   - HIV dementia, neurosyphilis
   - Autoimmune encephalitis, CNS vasculitis

═══════════════════════════════════════════════════════════════════════════
PHASE 4: CLASSIFICATION DECISION
═══════════════════════════════════════════════════════════════════════════

Based on comprehensive analysis, determine:

**CLASSIFICATION**: ADRD or Non-ADRD

For ADRD classification, specify:
- **Specific Diagnosis**: Alzheimer's Disease, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia, Mixed, or Other ADRD
- **Confidence Level**: High, Moderate, Low (based on diagnostic certainty)
- **Severity Stage**:
  * Mild (CDR 0.5-1, MMSE 21-26): Noticeable symptoms, some functional impairment
  * Moderate (CDR 2, MMSE 10-20): Clear deficits, needs supervision
  * Severe (CDR 3, MMSE <10): Profound impairment, requires total care

For Non-ADRD classification, specify:
- **Alternative Diagnosis**: MCI, Depression, Delirium, Metabolic, Medication-induced, Normal aging, Other
- **Evidence Against ADRD**: Why ADRD was ruled out

═══════════════════════════════════════════════════════════════════════════
PHASE 5: SUPPORTING EVIDENCE AND REASONING
═══════════════════════════════════════════════════════════════════════════

Document:

1. **Key Diagnostic Features Present**:
   - List evidence supporting ADRD or Non-ADRD classification
   - Quote specific findings from clinical record

2. **Criteria Met**:
   - Which diagnostic criteria are satisfied (NIA-AA, DSM-5, etc.)

3. **Differential Diagnoses Considered**:
   - What other conditions were considered?
   - Why were they ruled in or out?

4. **Inconsistencies or Ambiguities**:
   - Conflicting information
   - Missing data that would strengthen diagnosis
   - Atypical features

5. **Longitudinal Consideration**:
   - Is there documented progression over time?
   - Baseline function vs current function

6. **Biomarker Integration** (if available):
   - How do biomarkers support or refute clinical diagnosis?
   - Amyloid/tau status

═══════════════════════════════════════════════════════════════════════════
QUALITY STANDARDS
═══════════════════════════════════════════════════════════════════════════

✓ **COMPREHENSIVE**: Review ALL cognitive domains, functional status, behavior, neuroimaging
✓ **CRITERIA-BASED**: Apply established NIA-AA, DSM-5, consensus criteria
✓ **EVIDENCE-BASED**: Link classification to specific clinical findings
✓ **DIFFERENTIAL**: Consider and exclude alternative diagnoses
✓ **LONGITUDINAL**: Assess progression pattern over time
✓ **TRANSPARENT**: Clearly explain reasoning and confidence level

AVOID:
✗ Classification based on single finding
✗ Ignoring non-cognitive features (behavior, function, motor)
✗ Not considering reversible causes
✗ Overlooking imaging and biomarker data
✗ Failing to assess severity if ADRD diagnosed

═══════════════════════════════════════════════════════════════════════════
OUTPUT FORMAT
═══════════════════════════════════════════════════════════════════════════

Provide your classification in the structured JSON format specified in the schema, including:

1. **cognitive_assessment**: Formal testing scores, domains affected, progression
2. **functional_assessment**: ADL/IADL status, degree of impairment
3. **clinical_features**: Behavioral symptoms, neurological findings, imaging
4. **diagnostic_evaluation**: Labs, biomarkers, differential diagnoses
5. **classification**: ADRD vs Non-ADRD with specific diagnosis
6. **clinical_reasoning**: Criteria application, evidence synthesis, confidence factors

═══════════════════════════════════════════════════════════════════════════

{json_schema_instructions}

BEGIN YOUR COMPREHENSIVE ADRD CLASSIFICATION ASSESSMENT NOW.
